The Pharmaceutical Accountability Foundation is taking AbbVie to court in the Netherlands for allegedly overcharging Dutch citizens for rheumatoid arthritis drug Humira, The Financial Times reported.
The foundation said in a statement that AbbVie had abused its dominant position in the market from 2004 to 2018 “to keep prices and profits high”.
Related: AbbVie’s Humira Patent Suit Survives Antitrust Appeal
Wilbert Bannenberg, the PAF’s chair, said: “By making excessive profits, amounting to €68 per Dutch citizen, AbbVie has displaced other healthcare, and thus damaged the health of Dutch citizens.
“No doctor wants to be forced to prioritise one patient [or] treatment over another due to limited budgets.” Lawsuits surrounding access to drugs are nothing new.
The human rights element of the lawsuit brought by PAF against AbbVie is novel because it considers the overall effect of high prices on healthcare and society, even for those who did not directly access the drug, rather than focusing on one single molecule.
Featured News
CVS Health Explores Potential Breakup Amid Investor Pressure: Report
Oct 3, 2024 by
CPI
DirecTV Acquires Dish TV, Creating 20 Million-Subscriber Powerhouse
Oct 3, 2024 by
CPI
South Korea Fines Kakao Mobility $54.8 Million for Anti-Competitive Practices
Oct 3, 2024 by
CPI
Google Offers Settlement in India’s Antitrust Case Regarding Smart TVs
Oct 3, 2024 by
CPI
Attorney Challenges NCAA’s $2.78 Billion Settlement in Landmark Antitrust Cases
Oct 3, 2024 by
nhoch@pymnts.com
Antitrust Mix by CPI
Antitrust Chronicle® – Refusal to Deal
Sep 27, 2024 by
CPI
Antitrust’s Refusal-to-Deal Doctrine: The Emperor Has No Clothes
Sep 27, 2024 by
Erik Hovenkamp
Why All Antitrust Claims are Refusal to Deal Claims and What that Means for Policy
Sep 27, 2024 by
Ramsi Woodcock
The Aspen Misadventure
Sep 27, 2024 by
Roger Blair & Holly P. Stidham
Refusal to Deal in Antitrust Law: Evolving Jurisprudence and Business Justifications in the Align Technology Case
Sep 27, 2024 by
Timothy Hsieh